At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AEMD Aethlon Medical
Trading 07-20 12:26:40 EDT
0.6225
-0.0249
-3.85%
High0.6398Low0.6010Vol39.90K
Open0.6390D1 Closing0.6474Amplitude5.99%
Mkt Cap1.64MTradable Cap1.63MTotal Shares2.63M
T/O24.61KT/O Rate1.53%Tradable Shares2.61M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Aethlon Medical Reports Biomarker Shifts in Second Cohort of Hemopurifier Cancer Trial
Reuters  ·  07-13
Aethlon Medical Reports Biomarker Shifts in Second Cohort of Hemopurifier Cancer Trial
Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®
THOMSON REUTERS  ·  07-13
Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®
Aethlon Medical Prices $4 Million Offering with Warrants Exercisable at $0.71 on Shareholder Approval
Reuters  ·  07-06
Aethlon Medical Prices $4 Million Offering with Warrants Exercisable at $0.71 on Shareholder Approval
Aethlon Medical Announces Pricing of $4.0 Million Follow-on Offering Priced At-the-market Under NASDAQ Rules
THOMSON REUTERS  ·  07-06
Aethlon Medical Announces Pricing of $4.0 Million Follow-on Offering Priced At-the-market Under NASDAQ Rules
Aethlon Medical announces publication demonstrating potential of Hemopurifier
TIPRANKS  ·  06-26
Aethlon Medical announces publication demonstrating potential of Hemopurifier
Aethlon Medical Study Flags Long COVID Biomarker, Supports Hemopurifier Evaluation
Reuters  ·  06-26
Aethlon Medical Study Flags Long COVID Biomarker, Supports Hemopurifier Evaluation
Aethlon Medical posts corporate presentation on Hemopurifier blood-filtration platform targeting cancer, viral threats, transplant
Reuters  ·  06-18
Aethlon Medical posts corporate presentation on Hemopurifier blood-filtration platform targeting cancer, viral threats, transplant
Analysts Offer Insights on Healthcare Companies: Aethlon Medical (AEMD), Johnson & Johnson (JNJ) and Phreesia (PHR)
TIPRANKS  ·  06-12
Analysts Offer Insights on Healthcare Companies: Aethlon Medical (AEMD), Johnson & Johnson (JNJ) and Phreesia (PHR)
Aethlon Medical posts corporate presentation on Hemopurifier platform targeting cancer, viral threats, transplant
Reuters  ·  06-12
Aethlon Medical posts corporate presentation on Hemopurifier platform targeting cancer, viral threats, transplant
Aethlon Medical Reports Fiscal 2026 Results, Clinical Progress
TIPRANKS  ·  06-11
Aethlon Medical Reports Fiscal 2026 Results, Clinical Progress
Aethlon Medical Q4 EPS $0.40 Beats $(2.02) Estimate
Benzinga  ·  06-11
Aethlon Medical Q4 EPS $0.40 Beats $(2.02) Estimate
Aethlon Medical FY26 net loss narrows 46.58% to $7.2 million
Reuters  ·  06-11
Aethlon Medical FY26 net loss narrows 46.58% to $7.2 million
Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
THOMSON REUTERS  ·  06-11
Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  06-10
Calendar of U.S. Earnings Expected in the Week Ahead
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  06-08
Calendar of U.S. Earnings Expected in the Week Ahead
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  06-05
Calendar of U.S. Earnings Expected in the Week Ahead
Aethlon Medical updates ATM program, authorizes up to $542,716 in additional common stock sales
Reuters  ·  06-04
Aethlon Medical updates ATM program, authorizes up to $542,716 in additional common stock sales
Aethlon Medical to release fiscal year-end results, host conference call
Reuters  ·  06-02
Aethlon Medical to release fiscal year-end results, host conference call
Aethlon Medical Inc: Hemopurifier, Though Investigational, Showed Rapid Viral Reduction in One Ebola Patient in Germany
THOMSON REUTERS  ·  05-21
Aethlon Medical Inc: Hemopurifier, Though Investigational, Showed Rapid Viral Reduction in One Ebola Patient in Germany
Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness
THOMSON REUTERS  ·  05-21
Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness

Introduction

Company Name.
Aethlon Medical
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.
Issue price:
--